Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19
Lavilla Olleros et al.,
Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19,
PLOS ONE, doi:10.1371/journal.pone.0261711
Retrospective 14,921 hospitalized patients in Spain, showing lower mortality with HCQ treatment.
risk of death, 36.2% lower, RR 0.64, p < 0.001, treatment 2,285 of 12,772 (17.9%), control 774 of 2,149 (36.0%), NNT 5.5, adjusted per study, odds ratio converted to relative risk, multivariable.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Lavilla Olleros et al., 21 Jan 2022, retrospective, Spain, peer-reviewed, 22 authors.
Abstract: PLOS ONE
RESEARCH ARTICLE
Use of glucocorticoids megadoses in SARSCoV-2 infection in a spanish registry: SEMICOVID-19
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Lavilla Olleros C, Ausı́n Garcı́a C, Bendala
Estrada AD, Muñoz A, Wikman Jogersen PE,
Fernández Cruz A, et al. (2022) Use of
glucocorticoids megadoses in SARS-CoV-2
infection in a spanish registry: SEMI-COVID-19.
PLoS ONE 17(1): e0261711. https://doi.org/
10.1371/journal.pone.0261711
Editor: Aleksandar R. Zivkovic, Heidelberg
University Hospital, GERMANY
Received: July 4, 2021
Accepted: December 7, 2021
Cristina Lavilla Olleros ID1☯*, Cristina Ausı́n Garcı́a1☯, Alejandro David Bendala Estrada1☯,
Ana Muñoz2, Philip Erick Wikman Jogersen ID3, Ana Fernández Cruz4, Vicente Giner
Galvañ3, Juan Antonio Vargas4, José Miguel Seguı́ Ripoll3, Manuel Rubio-Rivas5,
Rodrigo Miranda Godoy6, Luis Mérida Rodrigo7, Eva Fonseca Aizpuru ID8,
Francisco Arnalich Fernández9, Arturo Artero10, Jose Loureiro Amigo11, Gema
Marı́a Garcı́a Garcı́a ID12, Luis Corral Gudino ID13, Jose Jiménez Torres ID14, JoséManuel Casas-Rojo15‡, Jesús Millán Núñez-Cortés1‡, On behalf of the SEMI-COVID-19
Network¶
1 General Internal Medicine Department, Hospital Universitario Gregorio Marañón, Madrid, Spain, 2 General
Internal Medicine Department, Infanta Cristina Hospital: Hospital Universitario Infanta 2 Cristina, ParlaMadrid, Spain, 3 General Internal Medicine Department, Hospital Universitario San Juan de Alicante, San
Juan de Alicante-Alicante, Spain, 4 General Internal Medicine Department, Hospital Universitario Puerta de
Hierro, Madrid, Spain, 5 General Internal Medicine Department, H. Univ. de Bellvitge, L’Hospitalet de
Llobregat, Barcelona, Spain, 6 General Internal Medicine Department, 12th of October University Hospital:
Hospital Universitario 12 de Octubre, Madrid, Spain, 7 General Internal Medicine Department, Hospital Costa
del Sol, Málaga, Spain, 8 General Internal Medicine Department, Hospital de Cabueñes: Hospital de
Cabuenes, Gijón, Spain, 9 General Internal Medicine Department, La Paz University Hospital: Hospital
Universitario La Paz, Madrid, Spain, 10 General Internal Medicine Department, Hospital Universitario Dr
Peset: Hospital Universitario Doctor Peset, Valencia, Spain, 11 General Internal Medicine Department,
Hospital de Sant Joan Despı́ Moisès Broggi: Hospital de Sant Joan Despi Moises Broggi, Barcelona, Spain,
12 General Internal Medicine Department, University Hospital Complex Badajoz: Complejo Hospitalario
Universitario de Badajoz, Badajoz, Spain, 13 Hospital Universitario Rio Ortega, Valladolid, Spain, 14 General
Internal Medicine Department, Hospital Reina Sofı́a: Hospital Reina Sofia, Córdoba, Madrid, Spain,
15 General Internal Medicine Department, Infanta Cristina Hospital: Hospital Universitario Infanta Cristina,
Parla-Madrid, Spain
☯ These authors contributed equally to this work.
‡ These authors also contributed equally to this work.
¶ Membership of the SEMI-COVID-19 Network is provided in the Acknowledgments.
* cristinalavillaolleros@gmail.com
Published: January 21, 2022
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is available here:
https://doi.org/10.1371/journal.pone.0261711
Copyright: © 2022 Lavilla Olleros et..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit